Cel­gene and blue­bird make a 'break­through' on BC­MA-tar­get­ing CAR-T; An­oth­er can­cer drug biotech gar­ners $39M start­up round for I/O work

→ Cel­gene $CELG and its part­ners at blue­bird bio $BLUE can add boast­ing rights to the FDA’s break­through drug pro­gram for their close­ly watched work on the mul­ti­ple myelo­ma CAR-T bb2121. Reg­u­la­tors are mak­ing a com­mit­ment to help speed along a new BC­MA-tar­get­ing ther­a­py that has post­ed some stel­lar clin­i­cal re­sults in an ear­ly-stage study. It will al­so help es­tab­lish its po­si­tion in what is emerg­ing as a race with Leg­end Biotech and its part­ners at J&J on a ri­val pro­gram that has al­so wowed in­ves­ti­ga­tors in the field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER